Viking Global Investors logo

Viking Global Investors

North America, Connecticut, United States, Stamford

Description

Viking Global Investors, founded in 1999 by O. Andreas Halvorsen, is a prominent investment firm headquartered in Stamford, Connecticut. Initially established as a hedge fund, Viking has grown into a multi-strategy firm known for its rigorous fundamental analysis and global investment approach. While its roots are in long/short equity strategies within public markets, the firm has diversified its capabilities to include significant private investments, particularly in growth equity and late-stage venture opportunities across various sectors and geographies.

The firm's investment philosophy centers on deep, bottom-up research to identify high-quality companies with strong growth prospects. Viking Global Investors manages a substantial pool of capital, with assets under management typically fluctuating in the tens of billions of dollars; for instance, reports in early 2023 indicated AUM around $30 billion. This considerable financial capacity allows Viking to take meaningful positions in both publicly traded companies and private enterprises, often holding investments for extended periods to realize long-term value.

Viking's private investment arm actively participates in large funding rounds for innovative companies poised for significant expansion. These investments are not typical early-stage venture capital checks but rather substantial capital injections into mature private companies or those nearing an IPO. For example, the firm has deployed capital in the range of $50 million to $500 million for individual private deals, often as part of larger syndicates. Their private portfolio spans diverse industries, including biotechnology, enterprise software, fintech, and consumer internet, reflecting their broad sector expertise and global reach.

Through its integrated public and private market expertise, Viking Global Investors seeks to capitalize on disruptive trends and exceptional management teams. The firm's ability to leverage insights from both public and private valuations provides a unique edge, enabling them to identify and support companies that are transforming their respective industries. This comprehensive approach underscores Viking's position as a sophisticated and influential player in the global investment landscape.

Investor Profile

Viking Global Investors has backed more than 174 startups, with 11 new investments in the last 12 months alone. The firm has led 63 rounds, about 36% of its total and boasts 43 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Series A, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Canada, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Therapeutics.
  • Led 3 rounds in the past year.
  • Typical check size: $50M – $500M.

Stage Focus

  • Series B (21%)
  • Series A (17%)
  • Series C (14%)
  • Series D (10%)
  • Series E (7%)
  • Private Equity (7%)
  • Series Unknown (6%)
  • Seed (5%)
  • Post Ipo Equity (4%)
  • Series F (3%)

Country Focus

  • United States (86%)
  • Canada (4%)
  • United Kingdom (4%)
  • China (1%)
  • Mexico (1%)
  • Brazil (1%)
  • Ireland (1%)
  • Israel (1%)
  • Switzerland (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
  • Biopharma
  • Software
  • Life Science
  • Saas
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Viking Global Investors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 14
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 12
CA
North America, Massachusetts, United States, Boston
Co-Investments: 17
Casdin Capital
North America, New York, United States, New York
Co-Investments: 12
T. Rowe Price
North America, Maryland, United States, Baltimore
Co-Investments: 12
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 15
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 21
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 11
Janus Henderson Investors
Europe, England, United Kingdom, London
Co-Investments: 10
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 11

Which angels does Viking Global Investors often collaborate with?

KP
North America, California, United States, Los Angeles
Shared Deals: 4
AK
North America, Pennsylvania, United States, Philadelphia
Shared Deals: 2
BG
North America, Washington, United States, Seattle
Shared Deals: 4
PG
North America, California, United States, Los Angeles
Shared Deals: 2
AO
North America, California, United States, San Francisco
Shared Deals: 2
KC
North America, Minnesota, United States
Shared Deals: 2
PR
North America, California, United States, Los Angeles
Shared Deals: 2
JS
North America, New York, United States, New York
Shared Deals: 2
AZ
North America, California, United States, Los Angeles
Shared Deals: 2
Shared Deals: 2

What are some of recent deals done by Viking Global Investors?

Antheia

Menlo Park, California, United States

Antheia uses synthetic biology to produce biosynthetic KSMs and APIs for essential medicines through engineered microbial fermentation.

BiotechnologyHealth CareManufacturingPharmaceutical
Series CJun 3, 2025
Amount Raised: $56,000,000
ORIC Pharmaceuticals

South San Francisco, California, United States

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

BiopharmaBiotechnologyHealth CarePharmaceuticalTherapeutics
Post Ipo EquityMay 28, 2025
Amount Raised: $125,000,000
AssetWatch

Westerville, Ohio, United States

AssetWatch is a deployable, remote, end-to-end condition monitoring solution providing predictive insight to enable proactive maintenance.

Big DataIndustrial AutomationInternet of ThingsMachine LearningPredictive Analytics
Series CApr 30, 2025
Amount Raised: $75,000,000

Nova Anchora is a biopharmaceutical company advancing a corrective protein therapy for DEB, a severe rare skin disease

Biotechnology
Series UnknownApr 29, 2025
Canopy

Draper, Utah, United States

Canopy offers a cloud-based Practice Management solution for Accounting professionals.

AccountingBillingCRMDocument ManagementPaymentsProject ManagementSoftware
Series CApr 23, 2025
Amount Raised: $70,000,000
Neurona Therapeutics

San Francisco, California, United States

Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.

BiotechnologyHealth CareTherapeutics
Series FApr 3, 2025
Amount Raised: $102,000,000
Valsoft

Montréal, Quebec, Canada

Valsoft specializes in the acquisition and growth of vertical-market software enterprises.

Business DevelopmentSoftware
Private EquityDec 26, 2024
Amount Raised: $150,000,000
Metsera

New York, New York, United States

Metsera is a biopharmaceutical company that develops medicines for obesity and metabolic diseases.

BiopharmaHealth CareMedicalPharmaceutical
Series BNov 13, 2024
Amount Raised: $215,000,000
Triveni Bio

Watertown, Massachusetts, United States

Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.

BiotechnologyHealth CareMedicalTherapeutics
Series BOct 2, 2024
Amount Raised: $115,000,000
Humaneva

Raleigh, North Carolina, United States

Humaneva is a healthacare research company that offers reliable clinical research data that empowers the medical community.

Clinical TrialsHealth CareOutpatient Care
Private EquitySep 24, 2024
Amount Raised: $50,000,000